CNBX · CNBX Pharmaceuticals Inc. · Financials
$0.00
+0.00 (+0.00%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 24, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.”View the 10-Q filed Jun 24, 2026
Market Cap
$160,576
Shares
1.61B
Volume · Oct 2
500K
Avg daily vol (3M)
8.24M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
-100%
FY2025
Net Income
-$313.98K
+54.8%
FY2025
Gross Margin
100%
0pp
FY2017
Operating Margin
-448.31%
-221.2pp
FY2024
Diluted EPS
$0.00
+100%
FY2025
Operating Cash Flow
-$171.31K
+29.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $130.07K | $410.17K | $29.96K | $0 | $7157 | $9843 | $9601 | $5684 | $112.5K | $0 | — | — | — | — | — | — | — | — | — | — | |
| — | -$39.81K | -$16.8K | — | — | — | — | -$18.35K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | $5684 | $112.5K | $0 | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | 100% | 100% | — | — | — | — | — | — | — | — | — | — | — | |
| $0 | $0 | $194.79K | $431.57K | $1.18M | $1.77M | $1.68M | $1.54M | $1M | $246.94K | $177.61K | $139.44K | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $20.25K | $60K | $288.16K | $422.02K | $287.46K | $960 | $62.72K | $0 | — | — | — | — | — | — | — | — | — | |
| $429.46K | $271.69K | $518.43K | $909.98K | $1.8M | $828.64K | $1.31M | $1.48M | $2.39M | $1.33M | $214.61K | $334.35K | $40.44K | $100 | $45 | — | $2180 | — | — | — | — | — | |
| $429.46K | $271.69K | $713.21K | $1.34M | $2.98M | $2.6M | $3.05M | $3.31M | $3.82M | $1.86M | $393.18K | $536.5K | $216.13K | $58.11K | — | — | — | — | — | — | — | — | |
| $83.72K | — | — | — | — | — | — | — | — | — | — | — | — | $58.11K | $1652 | $144.41K | $111.17K | — | — | — | — | — | |
| -$429.46K | -$271.69K | -$583.14K | -$931.38K | -$2.95M | -$2.6M | -$3.04M | -$3.3M | -$3.81M | -$1.85M | -$280.68K | -$536.5K | -$216.13K | -$58.11K | — | — | — | — | — | — | — | — | |
| — | — | -448.31% | -227.07% | -9860.37% | — | -42524.12% | -33563.01% | -39670.12% | -32616.1% | -249.49% | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $852 | $4373 | $7178 | $3026 | $971 | $179 | — | — | — | — | — | — | — | — | |
| $51.94K | $42.29K | $23.12K | $52.62K | $782.08K | $594.27K | -$4.42M | $4.44M | $32.11K | -$69.03K | -$27.89K | -$3026 | -$3009 | $1710 | — | — | — | — | — | — | — | — | |
| — | — | — | — | $0 | $0 | $105.88K | $142.23K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$541.39K | -$219.14K | -$56.4K | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | $0 | $0 | — | — | — | — | — | — | — | — | |
| -$462.09K | -$313.98K | -$695.2K | -$3.71M | -$3.72M | -$3.19M | -$7.47M | $1.13M | -$3.78M | -$1.93M | -$307.18K | -$541.39K | -$270.01K | -$56.4K | -$1652 | -$107.31K | -$114.98K | -$114.92K | -$27.46K | -$23.2K | -$20.02K | -$1800 | |
| — | — | -534.46% | -904.57% | -12428.23% | — | -104337.91% | 11510.41% | -39335.66% | -34022.54% | -273.05% | — | — | — | — | — | — | — | — | — | — | — | |
| -$462.09K | -$313.98K | -$695.2K | -$3.71M | -$4.39M | -$2.33M | -$13.05M | $3.94M | -$3.78M | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| USD/shares | $0.00 | $0.00 | -$0.02 | -$0.42 | -$3.59 | -$0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $0.00 | $0.00 | -$0.02 | -$0.42 | -$3.59 | -$0.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 90.65M | 30.25M | 8.82M | 1.22M | 138.52M | 1.12M | 1.1M | 1M | 919.84K | 860.49K | 839.22K | 430.27K | 11.34K | 5668.35 | 5668.35 | — | — | — | — | — | — |
| shares | — | 90.65M | 30.25M | 8.82M | 1.22M | 138.52M | 1.12M | 1.1M | 1M | 919.84K | 860.49K | 839.22K | 430.27K | 11.34K | 5668.35 | 5668.35 | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of convertible notes payable | 2026-05-31 | USD 1,047,204 | 10-Q filed 2026-06-24 |
| Short-term borrowings | 2026-05-31 | USD 120,000 | 10-Q filed 2026-06-24 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 6.40×
EV/EBIT
—
Biotechnology median 21.72×
P/E (TTM)
—
Biotechnology median 17.50×